- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02135809
Pancreatic Metal Stents in Chronic Pancreatitis
July 8, 2019 updated by: Boston Scientific Corporation
Fully Covered Self Expanding Metal Stents (FCSEMS) for Refractory Pancreatic Duct Strictures in Patients With Chronic Pancreatitis
The purpose of this study is to document the performance of a new Fully Covered Self Expanding Metal Stents (FCSEMS) for treatment of refractory pancreatic duct strictures in patients with painful chronic pancreatitis.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This study is a prospective, single arm, pre-approval study.
Treatment of 10 patients will take place at 1-3 clinical centers in two phases.
Phase 1 will include treatment of five patients with a three month stent indwell period at one clinical center.
Phase 2 will include treatment of five additional patients with a 3-6 month stent indwell period at 1-3 clinical centers.
Expected duration of participation for each patient is approximately 27 months for Phase 1 and approximately 27-30 months for Phase 2. All patients, regardless of phase, will be followed for 24 months after stent removal.
Post-removal follow-up visits will occur at 1, 3, 6, 12, 18 and 24 months.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brussels, Belgium, B-1070
- ULB Erasme Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18 or older
- Willing and able to comply with study procedures and follow-up schedule and provide written informed consent to participate in study
- Chronic pancreatitis of Cremer Type IV (Segmental pancreatitis of the head of the pancreas). See Appendix for Cremer classifications.
- Improvement of pancreatic pain during previous placement of a single pancreatic plastic stent
At least one of the following:
- Abdominal pain most probably related to chronic pancreatitis
- Recurrent dominant main pancreatic duct stricture in the head of the pancreas after prior indwell of pancreatic plastic stent(s) if pain score was available prior to preceding stent therapy. Recurrent stricture to be visually assessed at endoscopy and confirmed by recurrent main pancreatic duct dilatation at MRCP.
- Relapsing pain due to pancreatic duct stent blockage (with only one stent in place)
- Prior endoscopic pancreatic sphincterotomy (EPS), historically or to be provided at time of SEMS placement with informed patient consent.
Exclusion Criteria:
- Strictures caused by malignancies
- Biliary strictures caused by chronic pancreatitis
- Perforated duct.
- Ansa pancreatica or H anatomy
- Pancreatic duct stenoses not located in the head of the pancreas
- Failed access during an attempted ERCP on a prior date
- Prior pancreatic metal stent(s)
- Concurrent ESWL (Extracorporeal Shock Wave Lithotripsy) during the same treatment session
- Patients for whom endoscopic techniques are contraindicated.
- Patients who are currently enrolled in another investigational study that would directly interfere with the current study, without prior written approval from the sponsor
- Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational center that
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FCSEMS
Patients will receive the WallFlex Pancreatic Stent.
|
Temporary placement of the WallFlex Pancreatic Stent for treatment of refractory pancreatic duct strictures in patients with painful chronic pancreatitis.
Stent will be removed after 3-6 months indwell.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decrease of pain caused by refractory benign pancreatic duct strictures secondary to chronic pancreatitis
Time Frame: 3 months after study stent removal
|
Clinical success defined as decrease of pain caused by refractory benign pancreatic duct strictures secondary to chronic pancreatitis 3 months after stent removal compared to baseline prior to stent indwell period.
|
3 months after study stent removal
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence and severity of serious adverse events related to the stenting procedure, to the indwelling stent and/or to stent removal
Time Frame: Duration of study participation, an average of 27-30 months
|
Duration of study participation, an average of 27-30 months
|
|
Stent placement success
Time Frame: Study Stent Placement Procedure
|
Ability to deploy the stent in satisfactory position (Stent Placement Success).
Satisfactory position is defined as the stent being across the stricture, without visible impaction at an angle and distal end visible into the duodenum.
|
Study Stent Placement Procedure
|
Type of additional intervention within pancreatic duct
Time Frame: Duration of study participation, an average of 27-30 months
|
Duration of study participation, an average of 27-30 months
|
|
Stent removal success
Time Frame: Study Stent Removal
|
Successful stent removal (Stent Removal Success) defined as ability to remove stent endoscopically (grasper, snare, stent-in-stent) without serious stent removal-related adverse events
|
Study Stent Removal
|
Change of pain medication intake
Time Frame: Duration of study participation, an average of 27-30 months
|
Change of pain medication intake (type of medication) from baseline to each follow-up visit.
|
Duration of study participation, an average of 27-30 months
|
Number of device events
Time Frame: Duration of study participation, an average of 27-30 months
|
Device Events, including findings not associated with adverse events, such as but not limited to asymptomatic stent migration.
|
Duration of study participation, an average of 27-30 months
|
Stricture resolution of pancreatic duct after stent removal
Time Frame: Study Stent Removal
|
Assessment of pancreatic duct after stent removal compared to baseline, including ERCP to document extent of stricture resolution, extent of resolution of ductal dilation above the treated dominant stricture, and presence or absence of secondary ductal strictures at the level of where the proximal edge of the stent was located
|
Study Stent Removal
|
For patients who proceed to surgery, impact of prior SEMS on surgical outcomes.
Time Frame: Up to surgery
|
Up to surgery
|
|
Stent functionality
Time Frame: Up to time of study stent removal,average of 3-6 months on study
|
Stent functionality: Relief of pain caused by refractory benign pancreatic duct strictures secondary to chronic pancreatitis at 3 days, 2 weeks, 1 month, 2 months, 4 months (Phase 2 patients as applicable) and just prior to stent removal compared to baseline prior to stent placement, using established pancreatic pain score
|
Up to time of study stent removal,average of 3-6 months on study
|
Stricture Resolution at stent removal
Time Frame: Study Stent Removal
|
Stricture Resolution at stent removal, defined as pancreatographic confirmation of drainage of injected contrast medium after stent removal without visible persistent stricture
|
Study Stent Removal
|
Time to Recurrence of Stricture
Time Frame: Duration of study participation, an average of 27-30 months
|
Time to Recurrence of Stricture, established in patients who had stricture resolution at stent removal and defined as time elapsed from stent removal till recurrence of pain with associated documentation of narrowing of pancreatic duct.
Recurrence of stricture will be documented at the time it is identified and absence of stricture recurrence will be ascertained at 1, 3, 6, 12, 18 and 24 months after stent removal.
Pain will be documented using an established pancreatic pain score.
|
Duration of study participation, an average of 27-30 months
|
Reason for additional intervention within pancreatic duct
Time Frame: Duration of study participation, an average of 27-30 months
|
Duration of study participation, an average of 27-30 months
|
|
Timing of additional intervention within pancreatic duct
Time Frame: Duration of study participation, an average of 27-30 months
|
Duration of study participation, an average of 27-30 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jacques Deviere, MD, PhD, ULB Erasme Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2014
Primary Completion (Actual)
June 1, 2015
Study Completion (Actual)
March 30, 2017
Study Registration Dates
First Submitted
May 2, 2014
First Submitted That Met QC Criteria
May 8, 2014
First Posted (Estimate)
May 12, 2014
Study Record Updates
Last Update Posted (Actual)
July 9, 2019
Last Update Submitted That Met QC Criteria
July 8, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- E7093
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Pancreatic Duct Strictures
-
The Cleveland ClinicCompletedPancreatic Duct Strictures | Biliary Duct StricturesUnited States
-
Northwestern UniversityUniversity of Colorado, Denver; University of California, Los Angeles; University... and other collaboratorsWithdrawnCommon Bile Duct Stones | Bile Duct StricturesUnited States
-
Clinical Hospital ColentinaCompletedCholangiopancreatography, Endoscopic Retrograde | Biliary Strictures | Common Bile Duct Lithiasis | Bile Duct and Pancreatic TumorsCroatia, Italy, Romania
-
Catholic University of the Sacred HeartCompletedChronic Pancreatitis | Benign Biliary Strictures
-
University Hospital MuensterMerck Sharp & Dohme LLCCompletedSecondary Cholangitis | Bile Duct Strictures of Unknown OriginGermany
-
Boston Scientific CorporationCompletedBiliary Strictures Caused by Malignant NeoplasmsItaly, Belgium, France, Germany, India, Netherlands
-
Boston Scientific CorporationCompletedPost-ERCP Acute Pancreatitis | Pancreatic Duct Stricture | Pancreatic Duct Stones | Pancreatic Duct LeakageUnited States, Netherlands, Germany, India
-
University of FloridaCompletedBenign Biliary StricturesUnited States
-
Weill Medical College of Cornell UniversityUnknownInterventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal DisordersColorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Cholangiocarcinoma | Bile Duct Cancer | Cholangitis | Barrett's Esophagus | Gallstones | Choledocholithiasis | Bile Leak | Obstructive Jaundice | Duodenal Cancer | Pancreatic Pseudocysts | Ampullary Cancer | Biliary Strictures | Recurrent Pancreatitis | Bile Duct... and other conditionsUnited States
Clinical Trials on WallFlex Pancreatic Stent
-
Boston Scientific CorporationCompletedChronic PancreatitisUnited States, Netherlands, Italy, Canada, Belgium, India
-
Boston Scientific CorporationCompleted
-
Boston Scientific CorporationCompletedRefractory Benign Esophageal Strictures Caused by Caustic IngestionIndia
-
Foundation for Liver ResearchCompletedEsophageal Cancer | Esophageal StenosisNetherlands
-
University Hospital, AngersCompleted
-
Boston Scientific CorporationCompletedBiliary Strictures Caused by Malignant NeoplasmsItaly, Belgium, France, Germany, India, Netherlands
-
Second Affiliated Hospital, School of Medicine,...Ningbo No. 1 Hospital; Huizhou Municipal Central Hospital; Taizhou Hospital of... and other collaboratorsRecruiting
-
Karolinska University HospitalUniversity Hospital, Linkoeping; Lund University Hospital; Sahlgren´s University... and other collaboratorsUnknownHealing Time of Post Operative Pancreatic FistulasSweden
-
Helsinki University Central HospitalWithdrawnPancreatic Cancer | Biliary StasisFinland
-
AdventHealthCompletedWalled Off Necrosis | Necrotizing PancreatitisUnited States